Frank Steven 4

What Happened Frank Steven, a director of BioCryst Pharmaceuticals, received an award of 1,262 shares of common stock on 2026-05-29. The shares were recorded at $8.91 each, for a total reported value of $11,244. This was an award/compensation issuance (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-05-29; Form 4 filed: 2026-06-02 (timely).
• Transaction type: Award/Grant (code A).
• Shares acquired: 1,262 at $8.91 per share; total reported value $11,244.
• Shares owned after transaction: Not specified in the filing.
• Footnote: Shares were issued in lieu of 100% of the quarterly cash board retainer of $11,250 (footnote F1).
• No 10b5-1 plan, sale, exercise, or gift reported in this transaction.

Context This issuance reflects routine director compensation paid in stock rather than cash and is a common form of non-cash remuneration. Such awards are standard and do not by themselves indicate insider sentiment about the company’s stock price.